Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience
<p>Abstract</p> <p>Background</p> <p>Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted stand...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2005-03-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/5/30 |